DR Reddy S Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: DR Reddy S Laboratories Limited Pharmaceutical Export Portfolio Dataset — 50 Products, $310.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DR Reddy S Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 50 Products, $310.6M Trade | TransData Nexus

Product Portfolio — Top 30 by Export Value

DR Reddy S Laboratories Limited exports 50 pharmaceutical products across 19 therapeutic categories. Market leader (#1 exporter) in 5 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metoprolol	Cardiovascular	$72.0M	1,492	0.5%	12
2	Omeprazole	Gastrointestinal	$41.1M	822	0.8%	9
3	Fexofenadine	Antihistamines & Allergy	$15.3M	320	1.0%	10
4	Clopidogrel	Cardiovascular	$14.3M	286	5.7%	4
5	Esomeprazole	Gastrointestinal	$13.7M	273	3.0%	5
6	Magnesium	Vitamins & Supplements	$10.3M	228	2.8%	3
7	Cetirizine	Antihistamines & Allergy	$9.8M	196	5.5%	2
8	Montelukast	Respiratory	$9.4M	219	5.6%	4
9	Valsartan	Cardiovascular	$9.1M	181	0.5%	15
10	Sitagliptin	Diabetes & Endocrine	$9.0M	269	1.7%	13
11	Diclofenac	Analgesics & Antipyretics	$8.3M	165	2.3%	9
12	Bevacizumab	Advanced Oncology	$8.0M	160	1.5%	3
13	Sodium	Nutritional Supplements	$7.4M	148	2.0%	8
14	Tacrolimus	Immunosuppressants	$6.1M	134	0.4%	11
15	Ras	Ayurvedic & Herbal Products	$6.0M	119	1.9%	7
16	Rivaroxaban	Cardiovascular	$5.5M	138	9.9%	2
17	Fluoxetine	CNS & Psychiatric	$5.3M	185	0.3%	14
18	Ondansetron	Gastrointestinal	$5.2M	213	4.3%	6
19	Lansoprazole	Gastrointestinal	$5.2M	109	1.8%	8
20	Naproxen	Analgesics & Antipyretics	$4.0M	81	3.0%	6
21	Fluconazole	Antifungals	$3.9M	125	4.2%	6
22	Ofloxacin	Advanced Antibiotics	$3.7M	74	1.3%	1
23	Pantoprazole	Gastrointestinal	$3.7M	120	0.3%	15
24	Zinc	Vitamins & Supplements	$3.4M	68	4.3%	2
25	Ciprofloxacin	Antibiotics	$3.3M	65	0.9%	1
26	Rituximab	Advanced Oncology	$3.2M	64	16.7%	1
27	Doxorubicin	Oncology	$3.0M	61	3.8%	2
28	Dexamethasone	Corticosteroids	$2.8M	55	1.3%	1
29	Dasatinib	Advanced Oncology	$2.7M	54	2.7%	6
30	Bisacodyl	Gastrointestinal	$2.6M	107	3.3%	7

DR Reddy S Laboratories Limited exports 50 pharmaceutical products across 19 therapeutic categories with a total export value of $310.6M. The company is the #1 Indian exporter in 5 products: Ofloxacin, Ciprofloxacin, Rituximab, Dexamethasone. The top category is Cardiovascular (32.5% of portfolio), followed by Gastrointestinal (23.6%), reflecting a diversified portfolio where the top 5 products account for only 50.4% of total value.

Showing top 30 of 50 products. Contact us for complete data.

DR Reddy S Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Dr. Reddy's Laboratories Limited, established in 1984 by Kallam Anji Reddy, is a prominent Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. The company operates through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. As of March 2023, Dr. Reddy's employed approximately 24,832 individuals. The company's stock is listed on the National Stock Exchange of India under the ticker symbol DRREDDY.

2Manufacturing Facilities

Dr. Reddy's Laboratories maintains a robust manufacturing infrastructure with facilities in India, the United States, and the United Kingdom. These plants are equipped to produce a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. The company's manufacturing operations are certified by various regulatory bodies, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at Dr. Reddy's Laboratories is headed by CEO Erez Israeli, who oversees the company's strategic direction and operations. Mannam Venkatanarasimham serves as the Chief Financial Officer, responsible for financial management and reporting. Other key executives include Motupalli Venkata Ramana, Chief Executive Officer of Branded Markets - India and Emerging Countries, and Kallam Satish Reddy, Chairman of the Board.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does DR Reddy S Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Dr. Reddy's Laboratories has a significant presence in regulated markets such as the United States, Europe, the United Kingdom, Australia, and Japan. The company has obtained approvals for various Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) from the U.S. Food and Drug Administration (FDA). In Europe, Dr. Reddy's has received marketing authorizations for multiple products, adhering to the European Medicines Agency (EMA) guidelines. The company's products are also available in the UK, Australia, and Japan, meeting the respective regulatory requirements of these markets.

2Emerging Markets

Dr. Reddy's Laboratories has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in several countries across these regions, facilitated by the World Health Organization (WHO) prequalification, which enables access to these markets. This strategic expansion allows Dr. Reddy's to cater to a broader patient base and diversify its revenue streams.

3Geographic Strategy

DR Reddy S Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Dr. Reddy's Laboratories has registered multiple facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with Good Manufacturing Practices (GMP). The company has received approvals for various Abbreviated New Drug Applications (ANDAs) and has filed numerous Drug Master Files (DMFs), facilitating the marketing of its generic products in the U.S. market. Dr. Reddy's has a history of FDA inspections, with its facilities undergoing regular evaluations to maintain compliance with regulatory standards.

2WHO & EU GMP

Dr. Reddy's Laboratories holds World Health Organization (WHO) prequalification for several of its products, enabling access to international markets. The company's manufacturing facilities are certified with European Union Good Manufacturing Practice (EU GMP) certificates, ensuring adherence to high-quality standards required for marketing in European markets. Additionally, Dr. Reddy's complies with the European Directorate for the Quality of Medicines & HealthCare (EDQM) standards, further validating the quality of its products.

3CDSCO & Indian Regulatory

DR Reddy S Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Dr. Reddy's Laboratories faces competition from other major pharmaceutical companies in overlapping therapeutic categories. In the cardiovascular segment, the company competes with firms like Sun Pharmaceutical Industries and Lupin Limited. In the gastrointestinal category, competitors include Cipla Limited and Torrent Pharmaceuticals. In the antihistamines and allergy segment, Dr. Reddy's faces competition from companies such as Zydus Cadila and Alkem Laboratories. Despite this competition, Dr. Reddy's maintains a strong market presence through its diverse product portfolio and strategic market positioning.

2Key Differentiators

Dr. Reddy's Laboratories differentiates itself through its comprehensive product portfolio, encompassing over 190 medications and 60 active pharmaceutical ingredients (APIs). The company's focus on research and development enables the introduction of differentiated formulations and new chemical entities. Dr. Reddy's commitment to quality is demonstrated by its adherence to international standards, including WHO prequalification and EU GMP certifications. These factors contribute to the company's competitive advantage in the global pharmaceutical market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating DR Reddy S Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Dr. Reddy's Laboratories has a strong track record in the pharmaceutical industry, with a total export value of $310.6 million USD and 6,912 shipments across 50 products in 19 therapeutic categories. The company's top five products—Metoprolol, Omeprazole, Fexofenadine, Clopidogrel, and Esomeprazole—account for 50.4% of its export portfolio. Dr. Reddy's maintains consistency and reliability in its export operations, ensuring timely delivery and adherence to quality standards.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Dr. Reddy's Laboratories:

FDA Registration: Confirm the company's facilities are registered with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify that Dr. Reddy's products are prequalified by the World Health Organization (WHO), indicating adherence to international quality standards.

Frequently Asked Questions — DR Reddy S Laboratories Limited

How many pharmaceutical products does DR Reddy S Laboratories Limited export from India?

DR Reddy S Laboratories Limited exports 50 pharmaceutical products across 19 therapeutic categories. The top exports are Metoprolol ($72.0M), Omeprazole ($41.1M), Fexofenadine ($15.3M), Clopidogrel ($14.3M), Esomeprazole ($13.7M). Total export value is $310.6M.

What is DR Reddy S Laboratories Limited's total pharmaceutical export value?

DR Reddy S Laboratories Limited's total pharmaceutical export value is $310.6M, based on 6,912 verified shipments recorded in Indian Customs (DGFT) data.

In which products is DR Reddy S Laboratories Limited the #1 Indian exporter?

DR Reddy S Laboratories Limited is the #1 Indian exporter in 5 products: Ofloxacin (1.3% market share), Ciprofloxacin (0.9% market share), Rituximab (16.7% market share), Dexamethasone (1.3% market share).

What therapeutic categories does DR Reddy S Laboratories Limited cover?

DR Reddy S Laboratories Limited exports across 19 therapeutic categories. The largest are Cardiovascular (32.5%, 4 products), Gastrointestinal (23.6%, 7 products), Antihistamines & Allergy (8.4%, 3 products).

Get Full DR Reddy S Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

DR Reddy S Laboratories Limited

DR Reddy S Laboratories Limited — Export Portfolio & Destination Treemap

Who is DR Reddy S Laboratories Limited? — Company Overview & Market Position

What Does DR Reddy S Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

DR Reddy S Laboratories Limited Therapeutic Categories — 19 Specializations